Tm Bioscience Defers by One Year $2M Payment to Sirius in Biomarker Agreement | GenomeWeb
NEW YORK (GenomeWeb News) — Tm Bioscience today said it has amended its licensing agreement with Sirius Genomics to defer a $2 million payment that was due Sept. 5 until sometime in October 2007, or “90 days after completion of certain milestones by Sirius.”
 
Tm Bioscience’s patented materials include an FDA approved genotyping test for cystic fibrosis, as well as other tests based on the company’s Tag-it Universal Array platform.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.